NASC (Nascent Pharma Holdings) Cyclically Adjusted Revenue per Share: $0.00 (As of Sep. 2024)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.02
View Full Analysis

What is Nascent Pharma Holdings Cyclically Adjusted Revenue per Share?

Nascent Pharma Holdings NASC -0.01% 12 Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nascent Pharma Holdings's adjusted revenue per share for the three months ended in Sep. 2024 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-05), Nascent Pharma Holdings's current stock price is $0.01505. Nascent Pharma Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.00. Nascent Pharma Holdings's Cyclically Adjusted PS Ratio of today is .


Nascent Pharma Holdings  (OTCPK:NASC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nascent Pharma Holdings Cyclically Adjusted Revenue per Share Related Terms


Nascent Pharma Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Cyclically Adjusted Revenue per Share Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.20 4.29 4.69 4.80

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.83 4.80 4.84 4.86 0.00

NASC vs ALID, CPMD, PLSH: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Pharma Holdings Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Cyclically Adjusted PS Ratio falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nascent Pharma Holdings's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0/315.3010*315.3010
=0.000

Current CPI (Sep. 2024) = 315.3010.

Nascent Pharma Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.184 234.812 0.247
201503 0.714 236.119 0.953
201506 0.560 238.638 0.740
201509 0.358 237.945 0.474
201512 0.615 236.525 0.820
201603 0.688 238.132 0.911
201606 0.781 241.018 1.022
201609 0.750 241.428 0.979
201612 0.719 241.432 0.939
201703 0.316 243.801 0.409
201706 0.419 244.955 0.539
201709 0.344 246.819 0.439
201712 1.267 246.524 1.620
201803 0.864 249.554 1.092
201806 1.833 251.989 2.294
201809 1.698 252.439 2.121
201812 2.422 251.233 3.040
201903 3.172 254.202 3.934
201906 3.987 256.143 4.908
201909 3.122 256.759 3.834
201912 3.134 256.974 3.845
202003 2.457 258.115 3.001
202006 0.820 257.797 1.003
202009 2.040 260.280 2.471
202012 1.466 260.474 1.775
202103 0.504 264.877 0.600
202106 0.258 271.696 0.299
202109 0.954 274.310 1.097
202112 0.700 278.802 0.792
202203 0.590 287.504 0.647
202206 0.377 296.311 0.401
202209 0.828 296.808 0.880
202212 0.161 296.797 0.171
202303 0.192 301.836 0.201
202306 0.076 305.109 0.079
202309 0.036 307.789 0.037
202312 0.012 306.746 0.012
202403 0.010 312.332 0.010
202406 0.005 314.175 0.005
202409 0.000 315.301 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Nascent Pharma Holdings (NASC) has a Cyclically Adjusted Revenue per Share of $0.00 as of Sep. 2024. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Cyclically Adjusted Revenue per Share too high?
Nascent Pharma Holdings' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Cyclically Adjusted Revenue per Share compare to ALID and CPMD?
Nascent Pharma Holdings' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price